A comprehensive analysis for pharma IP teams, portfolio managers, payer strategy leads, and institutional investors examining the structural economics, IP implications, and replicability of subscription-based drug financing.
Why Volume-Based Drug Pricing Is Breaking Down
The pharmaceutical industry’s dominant payment architecture, pay-for-each-unit-dispensed, worked well enough when drug costs were manageable and treatment volumes were predictable. Neither condition holds today. Between 2013 and 2015, inpatient prescription drug spending at U.S. hospitals increased 38.7%. In the two years that followed, total hospital and health system drug expenditure rose an additional 18.5% per admission, with outpatient adjusted admissions bearing a 28.7% jump in the same window. Those figures come from American Hospital Association data and represent a structural shift, not a pricing anomaly.
The volume-based model creates a direct, linear relationship between treatment access and budget exposure. Every additional patient treated adds a fixed marginal cost. For a state Medicaid program or a national health system running on a capped annual budget, that relationship forces rationing. Administrators do not ration because they want to. They ration because the payment architecture gives them no other option. The consequences are visible in utilization data, hospitalization rates, and disease prevalence statistics for conditions where cheap, effective cures exist but remain financially inaccessible at scale.
The economic logic of volume-based pricing made sense when drugs were cheap commodities. Branded biologics and small-molecule breakthroughs with list prices in the five and six figures per course have exposed its limits. A payer covering 50,000 hepatitis C patients at $20,000 per treatment course faces a $1 billion liability. Under traditional reimbursement, that number scales with every newly diagnosed or newly eligible patient. The result is that payers implement increasingly aggressive prior authorization criteria, step therapy requirements, and clinical gatekeeping rules, all of which restrict access to the patients the treatment was designed to reach.
Key Takeaways: The Volume-Based Breakdown
The core dysfunction is structural, not political. Volume-based pricing creates financial incentives that cap treatment rates irrespective of clinical benefit or public health priority. As drug costs rise, the gap between eligible patients and treated patients widens. The payer license agreement model, discussed in depth below, is the most operationally mature alternative currently in deployment.
The Access Paradox: Breakthrough Drugs Nobody Can Afford
Hepatitis C is the clearest example of this dynamic. Direct-acting antiviral regimens introduced after 2013 achieve sustained virologic response rates above 95%, which is functionally a cure for a disease that previously required lengthy, toxicity-prone interferon-based therapy. The science was a genuine breakthrough. The pricing architecture that accompanied it was not designed for mass deployment.
Before Louisiana implemented its subscription model, the state had approximately 39,000 Medicaid beneficiaries and incarcerated individuals with active hepatitis C infections. Its annual treatment throughput was roughly 1,000 patients. That is a treatment rate below 3%. The rest continued to accumulate liver fibrosis, progressed toward cirrhosis and hepatocellular carcinoma, and eventually consumed far more healthcare resources in downstream complications than a front-loaded treatment course would have cost. The volume-based model optimized for short-term budget control and produced long-term cost inflation.
This is the access paradox in concrete terms: a curative therapy exists, a large treatable population exists, the public health and economic case for treatment is clear, and most patients still go untreated. The barrier is entirely financial, and it is a product of payment design rather than therapeutic limitation.
The same paradox appears in antibiotics, oncology, gene therapy, and rare disease. The specifics vary, but the structural problem repeats: breakthrough assets get priced for small, severely ill patient populations because volume-based reimbursement cannot support broad access at launch-level list prices. This pricing behavior is rational from a manufacturer’s perspective, self-defeating from a system perspective, and harmful from a patient perspective.
Key Takeaways: The Access Paradox
Utilization data consistently shows that prior authorization restrictions and budget-driven rationing concentrate treatment among the sickest patients, precisely those for whom early intervention would have been most cost-effective. The access paradox is not solved by lowering list prices alone. It requires restructuring the relationship between payment, volume, and access.
Value-Based Pricing’s Structural Failure
Value-based pricing has been the theoretical alternative to market-rate and reference-based pricing for over a decade. Health technology assessment bodies across Europe and the Institute for Clinical and Economic Review in the United States have built frameworks to translate clinical evidence into price recommendations. The approach has genuine merit: it ties reimbursement to demonstrated benefit and forces manufacturers to defend their pricing with outcome data rather than market power.
The problem is implementation. Value-based pricing lacks standardization across markets, therapeutic areas, and patient subpopulations. Experts have described it as ‘more of an art than science’ due to this standardization gap, and the description is accurate. Cost-effectiveness thresholds, quality-adjusted life year calculations, and time horizon assumptions all vary by jurisdiction. A drug that clears NICE’s cost-effectiveness bar in England may fail Germany’s IQWIG benefit assessment under identical clinical data. Manufacturers face fragmented, inconsistent valuations across markets, which makes global pricing strategy extremely difficult.
The model also performs poorly for therapeutic categories where the traditional benefit-per-patient calculus breaks down. Orphan drugs for rare diseases serve populations too small to generate statistically powered cost-effectiveness data. Gene therapies deliver one-time interventions whose durability is uncertain over decade-long time horizons, making net present value calculations highly sensitive to discount rate assumptions. Antibiotic stewardship explicitly suppresses utilization of the most effective reserved-use agents, which means their volume-based reimbursement never reflects their public health value.
Value-based pricing resolves some problems that volume-based pricing creates, but it does not resolve the access paradox. A drug priced at its population-level value-based ceiling may still be priced above what any single patient, insurer, or government program can absorb on a per-unit basis. The subscription model addresses this directly by shifting the pricing basis from the individual treatment to the entire eligible population served by a payer over a defined period.
Key Takeaways: Value-Based Pricing Gaps
Value-based pricing improves the quality of the price-signal relationship but does not structurally resolve the volume-access tension. For curative therapies, antibiotics, and gene therapies specifically, alternative financing architectures are necessary. The payer license agreement model is better understood as a complement to value-based pricing than as a replacement for it.
The Payer License Agreement Model: Mechanics and Architecture
The payer license agreement (PLA), commercially known as the Netflix model for drug pricing, restructures pharmaceutical reimbursement along three axes. First, it shifts the unit of pricing from the individual patient to the full eligible population covered by a payer. Second, it links the negotiated fee to the incremental cost avoided by treating that population rather than to per-prescription list price. Third, it annuitizes payment across a contract period of five or more years, converting a variable, unpredictable expenditure into a fixed, forecastable liability.
Under a standard PLA, a payer (typically a state Medicaid program, a national health system, or a managed care organization covering a defined population) pays a flat subscription fee to a pharmaceutical manufacturer in exchange for unlimited access to specified drugs for all indicated patients within that population over the contract term. The marginal cost of treating each additional patient within the contracted population is zero once the subscription fee is paid.
This pricing basis change has profound implications. Under volume-based reimbursement, expanding treatment access directly increases costs. Under a PLA, expanding access is free. The payer’s financial incentive shifts from restricting treatment to maximizing appropriate treatment, since broader treatment reduces disease burden, lowers downstream complication costs, and improves population health outcomes that affect future budget cycles. The manufacturer’s incentive shifts from defending high per-unit prices to ensuring maximum appropriate utilization, since underutilization reduces the realized value delivered and weakens the case for renewing the subscription.
Variants of the basic PLA structure can incorporate nonlinear pricing provisions tied to utilization bands, outcomes-based adjustments that modify the subscription fee based on real-world efficacy data, and tiered population definitions that expand or contract coverage thresholds during the contract term. These modifications add structural sophistication but also negotiating complexity. The basic three-element architecture (population-level pricing, cost-avoidance valuation, multi-year annuitization) is the foundation that makes the model functionally distinct from traditional rebate arrangements.
A PLA is also operationally distinct from a closed formulary arrangement, though it produces similar formulary effects. Under a PLA, the contracted product becomes the preferred treatment for all indicated patients except those with specific clinical contraindications requiring an alternative. This creates a near-exclusive utilization pathway that serves both payer (consistent pricing) and manufacturer (volume certainty) interests simultaneously.
Key Takeaways: PLA Model Structure
The PLA’s three structural changes, population-level pricing basis, cost-avoidance valuation, and multi-year annuitization, are each individually incremental. Combined, they produce a fundamentally different economic relationship between a payer and a manufacturer. Analysts evaluating PLA proposals should examine all three elements, since contracts that adopt one or two without the third typically fail to achieve the access and budget-predictability benefits that make the model attractive.
Gilead Sciences and Epclusa: The IP Foundation That Made Louisiana Possible
No analysis of the PLA model’s hepatitis C implementation is complete without examining the intellectual property architecture that made it structurally feasible. Gilead’s position in the HCV market is built on one of the most valuable drug patent portfolios assembled in the small-molecule space.
Sofosbuvir’s Acquisition and Core IP
Gilead acquired Pharmasset in January 2012 for approximately $11.2 billion, at the time one of the largest pharmaceutical acquisitions in history. The asset Gilead was buying was primarily sofosbuvir, then in Phase II development. Sofosbuvir’s core compound patent, U.S. Patent No. 8,957,046, covers the nucleotide prodrug structure that gives the molecule its pan-genotypic potency and resistance barrier. That patent, along with related method-of-use and formulation patents, provides protection extending into the late 2020s, with the precise expiry dates in the Orange Book varying by specific claim family.
Gilead combined sofosbuvir with velpatasvir, a NS5A inhibitor with its own independent patent estate, to create Epclusa (sofosbuvir/velpatasvir), approved by the FDA in June 2016. Epclusa was the first single-tablet regimen approved for all six major HCV genotypes without genotype testing, which is a clinically significant differentiation for Medicaid and prison populations where genotype testing infrastructure is inconsistent. The combination patent filings add a secondary layer of IP protection to the sofosbuvir asset, extending the practical exclusivity window beyond the core compound patent expiry.
Asegua Therapeutics: The Authorized Generic Vehicle
Gilead created Asegua Therapeutics as a wholly-owned subsidiary specifically to market the authorized generic version of Epclusa. This is a well-established IP lifecycle management strategy. By launching its own authorized generic before third-party Paragraph IV filers could achieve approval, Gilead can maintain price control in the generic channel, capture value that would otherwise transfer to independent generic manufacturers, and offer payers a lower-price access point while protecting branded Epclusa’s list price in the commercial market.
For Louisiana’s subscription model, the state contracted with Asegua rather than with Gilead directly, purchasing the authorized generic form of Epclusa at a negotiated subscription fee. This structure allowed Gilead to participate in the public-payer subscription market through Asegua without creating reference pricing complications that could affect Epclusa’s commercial list price or international reference price calculations. The IP portfolio remained consolidated under Gilead, while commercial risk (underutilization of the subscription contract) sat with the state.
IP Valuation Implications for Portfolio Managers
From an IP valuation standpoint, Gilead’s HCV portfolio demonstrates how a subscription contract can extend the commercial life of an asset approaching generic entry. Sofosbuvir and velpatasvir have faced Paragraph IV challenges, and the authorized generic landscape for HCV drugs is competitive. A five-year state subscription contract guarantees revenue from the Medicaid channel through the contract term regardless of generic entry dynamics in the commercial market. For an IP portfolio that is approaching the back half of its exclusivity window, that guaranteed revenue stream has meaningful net present value.
Analysts valuing Gilead’s HCV IP estate should account for PLA-contracted revenue as a separate revenue segment with a different risk profile than commercial-channel branded sales. PLA revenue is less exposed to competitive generic erosion but more exposed to payer budget cycles and state-level policy changes. The contract structure also limits upside volume capture, since subscription fees are fixed even if eligible patient populations grow faster than projected.
Louisiana’s Hepatitis C Subscription: A Forensic Case Study
Louisiana’s PLA implementation, the first of its kind in the United States, is worth examining in forensic detail because every subsequent domestic implementation has drawn on its structural template. The state’s circumstances were not unusual. Its challenge was representative of what most Medicaid programs face with high-cost breakthrough therapies.
The Pre-Subscription Baseline
Before the PLA, Louisiana had approximately 39,000 Medicaid beneficiaries and incarcerated individuals with confirmed hepatitis C, and it treated roughly 1,000 per year. The drug expenditure cap for HCV treatment in fiscal year 2018 was $35 million. That figure was not a policy choice about what hepatitis C treatment was worth. It was a budget ceiling determined by competing Medicaid spending priorities. The treatment gap of 38,000 untreated patients was the direct output of volume-based pricing applied to a $94,000 average wholesale price treatment course.
The Competitive Bidding Process and Contract Award
The Louisiana Department of Health issued requests for proposals from pharmaceutical manufacturers in late 2018. Three companies submitted bids: AbbVie, Asegua Therapeutics, and Merck. This competitive structure was a deliberate design choice by state officials, who understood that a three-bidder field would generate price competition that a sole-source negotiation could not. The state received proposals covering different drug combinations, different contract structures, and different assumptions about eligible patient populations.
Louisiana selected Asegua Therapeutics in March 2019. The five-year contract began July 1, 2019, capped total spending at the existing $35 million annual budget, and provided unlimited access to the authorized generic form of Epclusa for all Medicaid beneficiaries and state prison inmates with HCV. The state’s treatment target was 10,000 patients by 2020, a tenfold increase over prior-year throughput, within the same nominal budget envelope.
Structural Lessons From the Louisiana Contract
Several structural features of Louisiana’s PLA deserve attention from teams designing similar programs elsewhere. The state maintained the existing $35 million budget as the subscription fee benchmark rather than negotiating downward from that figure, which preserved budget neutrality as the political argument for the program. The five-year term provided Asegua with sufficient revenue certainty to justify a per-treatment unit price well below Epclusa’s commercial list price. The treatment target of 10,000 patients was ambitious but epidemiologically defensible given the known prevalence data.
The contract also required the state to implement utilization infrastructure: treatment authorization processes, clinical care coordination, and patient identification outreach programs. A subscription fee without corresponding investment in patient identification and care navigation underdelivers on both access and public health impact. Louisiana’s experience shows that the subscription contract is necessary but not sufficient. The operational infrastructure to identify, navigate, and treat patients at scale requires parallel investment.
Key Takeaways: Louisiana
Louisiana demonstrated that a state Medicaid program can achieve a tenfold increase in HCV treatment throughput without increasing drug expenditure by restructuring the payment architecture rather than the treatment protocol. The competitive bidding process was essential to achieving favorable terms. The five-year term length was long enough to deliver manufacturer revenue certainty and short enough to preserve state flexibility as the HCV treatment landscape evolves.
Washington State’s Elimination Framework
Washington adopted a PLA model for hepatitis C with a programmatic ambition that went beyond Louisiana’s: complete HCV elimination from the state by 2030. This goal required not just a subscription pricing contract but a statewide public health strategy to find, test, link, and treat patients who were not already engaged with the healthcare system.
Washington’s subscription model differed from Louisiana’s in its integration with a broader disease elimination program. The state deployed screening expansion initiatives targeting populations with elevated HCV prevalence, including people who inject drugs, individuals experiencing homelessness, and those in the criminal justice system. The subscription contract made expanded screening economically rational in a way that volume-based pricing could not: every newly identified patient who initiates treatment adds no marginal drug cost to the budget.
The elimination framework created a different calculus for the manufacturer as well. A state committed to a 2030 elimination target has a strong programmatic incentive to sustain the subscription relationship, renew contracts as they expire, and maintain the operational infrastructure to generate treatment volume. For Gilead’s Asegua subsidiary, Washington represented a more durable commercial relationship than a straightforward budget-neutral access deal.
Key Takeaways: Washington State
Integrating a PLA with an explicit disease elimination target changes the program’s political durability and operational scope. States that adopt elimination goals create self-reinforcing incentives to maintain and expand treatment infrastructure, which supports subscription renewal and sustained manufacturer revenue. Teams designing PLA programs in other therapeutic areas should consider whether an analogous elimination or near-elimination goal is achievable, as it significantly strengthens the policy case for multi-year commitment.
The UK NHS Antimicrobial Subscription: Delinking Payment from Volume
The United Kingdom’s antimicrobial subscription program, developed under the National Health Service and the Department of Health and Social Care, addresses a market failure that is structurally different from hepatitis C but equally damaging. Antibiotic development has declined sharply over the past two decades because the volume-based payment model is fundamentally incompatible with responsible antibiotic stewardship.
Why the Standard Model Fails for Antibiotics
Antibiotics that treat drug-resistant infections should, by any rational stewardship principle, be used sparingly and reserved for patients with confirmed resistant infections. But volume-based reimbursement pays manufacturers only when their drugs are prescribed. A manufacturer that develops a novel carbapenem-sparing agent for carbapenem-resistant Enterobacteriaceae faces a commercial reality where appropriate use means minimal revenue. The drug needs to exist in hospital formularies as a ready reserve, but generating that drug’s development cost requires volume that responsible use prohibits.
This market failure is not hypothetical. Novartis announced the reduction of its antibiotic R&D operations in late 2018. Melinta Therapeutics filed for Chapter 11 bankruptcy in 2019 despite having FDA-approved antibiotics on the market. Achaogen dissolved its operations the same year. The volume-based model was actively dismantling the antibiotic pipeline at a time when antimicrobial resistance was escalating as a public health threat.
The NHS Subscription Pilot: Structure and Participants
The NHS launched a three-year antimicrobial subscription pilot under its 2019-2024 antimicrobial resistance action plan. The program selected two antibiotics through a formal value assessment process. Cefiderocol, developed by Shionogi and marketed in the UK as Fetcroja, received one subscription contract. Ceftazidime-avibactam, a combination product developed under a collaboration between AstraZeneca and Pfizer and marketed as Zavicefta, received the second. Annual subscription fees for each were reported at approximately £10 million per product, paid regardless of prescription volume.
The subscription fee decoupled Shionogi’s and Pfizer’s revenue from utilization, which is precisely the structural correction the antibiotic market failure requires. Both companies can plan R&D investment with some revenue certainty from the UK channel. Hospitals can list these drugs on formulary without budget exposure proportional to utilization. Stewardship programs can restrict use to appropriate patients without reducing manufacturer income. All three objectives are served by a single structural change in the payment mechanism.
Key Takeaways: UK NHS Antibiotics
The NHS antimicrobial subscription demonstrates that the PLA architecture generalizes across therapeutic areas when the underlying market failure involves a misalignment between clinical use constraints and volume-based revenue. For R&D portfolio managers at companies with antibiotic assets, the NHS subscription model establishes a proof-of-concept payment mechanism that other national health systems can replicate. France, Germany, and Sweden have all conducted feasibility assessments of similar models.
Pfizer and Shionogi: IP Valuation in the Antibiotic Subscription Space
Pfizer’s Ceftazidime-Avibactam IP Position
Ceftazidime is a third-generation cephalosporin with a long genericized history. Avibactam, the beta-lactamase inhibitor that gives the combination its activity against resistant gram-negatives, was developed by AstraZeneca’s infection biology unit and licensed to Pfizer for commercialization in North America and Europe. The key IP asset in ceftazidime-avibactam is the avibactam moiety, covered by composition-of-matter and method-of-use patents that extend protection into the mid-2030s in major markets.
For Pfizer’s IP team, the NHS subscription contract represents a different kind of asset monetization than commercial-channel hospital formulary sales. The subscription fee is a fixed annual payment that provides floor-level revenue during the period when market penetration for reserved-use antibiotics would otherwise be minimal. It also establishes a reimbursement framework that other payers can reference, creating a template for subscription contracts in Germany, the United States, and other markets where antibiotic stewardship policies suppress utilization.
Shionogi’s Cefiderocol: Siderophore Cephalosporin IP
Cefiderocol is mechanistically distinct from other beta-lactams. Its siderophore conjugate structure allows it to exploit iron transport systems to penetrate gram-negative bacterial outer membranes, giving it activity against carbapenem-resistant organisms including Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The composition-of-matter patents covering the cefiderocol siderophore-cephalosporin structure are Shionogi’s core IP asset in this space, with market exclusivity extending into the 2030s.
Shionogi’s IP position is globally significant because no equivalent siderophore-conjugated beta-lactam exists in other companies’ late-stage pipelines. The NHS subscription contract gave Shionogi a guaranteed annual revenue stream from the UK market at a time when the commercial antibiotic market’s structural dysfunction was its primary barrier to R&D investment recovery. From a valuation standpoint, NHS subscription revenue should be modeled as a risk-adjusted annuity with renewal probability tied to NHS budget cycles and AMR policy continuity, not as a commercial sales projection.
IP Valuation Framework for Antibiotic Subscription Assets
Portfolio managers valuing antibiotic assets under a subscription payment environment should apply a modified discounted cash flow framework that accounts for several factors absent from standard pharmaceutical valuation models. Subscription revenue is more predictable but growth-limited compared to commercial-channel revenue. The absence of volume-based upside means the valuation ceiling is lower, but the floor is more defensible. Renewal probability depends on payer budget continuity and policy environment rather than competitive dynamics, so political risk models are more relevant than market share projections. Stewardship program uptake affects the drug’s reputation and regulatory standing but does not affect subscription income, creating a partial decoupling of clinical and commercial performance metrics.
AbbVie’s Mavyret and the Competitive Dynamics of HCV Bidding
AbbVie’s glecaprevir/pibrentasvir combination, marketed as Mavyret in the United States and Maviret in Europe, competed directly with Gilead’s products in Louisiana’s subscription bidding process. Mavyret’s clinical differentiation is its eight-week treatment duration for treatment-naive patients without cirrhosis (compared to twelve weeks for most sofosbuvir-based regimens), and its pan-genotypic coverage, which matches Epclusa’s profile.
Mavyret’s IP Architecture
Mavyret’s IP estate centers on the glecaprevir NS3/4A protease inhibitor and pibrentasvir NS5A inhibitor, both discovered internally at AbbVie’s North Chicago research facilities. AbbVie’s HCV patent portfolio includes composition-of-matter claims on both active moieties, combination formulation patents, and method-of-use patents covering pan-genotypic applications. The core patents extend into the early-to-mid 2030s in the United States, providing a longer runway than Gilead’s sofosbuvir estate from a patent cliff perspective.
The longer IP runway gave AbbVie a different strategic calculus in the Louisiana bidding process. AbbVie could price its subscription bid with a longer revenue recovery horizon in mind, since its branded products face generic competition later than Gilead’s. The fact that Asegua Therapeutics, Gilead’s authorized generic vehicle, won the Louisiana contract suggests that Gilead’s competitive bid, enabled by its willingness to use the authorized generic channel, was more aggressive on per-treatment unit economics than AbbVie’s branded-product offer.
Investment Strategy: HCV Asset Comparison for Portfolio Managers
Analysts comparing Gilead and AbbVie HCV assets for portfolio allocation should note that the two companies face different incentive structures for PLA engagement. Gilead, with its sofosbuvir compound patents maturing earlier, has stronger incentives to lock in multi-year subscription revenue through the authorized generic channel before generic erosion begins. AbbVie, with a longer exclusivity window on Mavyret’s core IP, has more flexibility to hold on commercial-channel pricing while selectively pursuing subscription contracts in markets where the public-payer channel represents incremental volume rather than cannibalization of commercial revenue.
The competitive HCV subscription market has also established that bidding processes with multiple manufacturer participants generate meaningfully better terms for payers than sole-source negotiations. Any state or health system replicating the Louisiana model should design the procurement process to attract at least three substantively differentiated bids.
Extending the Model: Gene Therapy, Orphan Drugs, and Chronic Disease
The hepatitis C and antibiotic implementations demonstrated that PLA-style subscription pricing works for curative or high-impact finite-course treatments in well-defined populations. The harder question is whether the model generalizes to other therapeutic categories with different clinical profiles.
Gene Therapy: The One-Time Treatment Valuation Problem
Gene therapies present the most extreme version of the access paradox. Treatments like Novartis’s Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy carry list prices above $2 million per patient. The clinical case for early treatment is clear: intervening before symptom onset in SMA-affected neonates identified through newborn screening produces dramatically better outcomes than treatment after symptom progression. The economic case is theoretically supportable: a one-time curative treatment in infancy may avoid decades of high-cost supportive care. But the upfront price is prohibitive for virtually any public payer without alternative financing mechanisms.
A gene therapy PLA could structure payment as a multi-year annuity tied to population prevalence data, with outcomes-based adjustments that reduce annual payments if treated patients do not maintain expected outcomes trajectories. This annuitized approach converts the single large payment into a sequence of smaller payments spread over five to ten years, matching the revenue stream to the therapeutic durability period. Several European health systems are exploring this architecture, though implementation has been slowed by the absence of long-term durability data for first-generation gene therapies and by regulatory uncertainty about how to manage outcomes-based payment adjustments across budget cycles.
Orphan Drugs: Population Size and Pricing Tension
The orphan drug market presents a different challenge. With patient populations often measured in hundreds or low thousands nationwide, subscription models face a scale problem: the eligible population covered by any single payer may be too small to justify the administrative overhead of a subscription contract negotiation. A Medicaid program with 200 eligible patients for a rare disease drug does not have meaningful negotiating power relative to the manufacturer.
The solution may be a cross-payer or cross-state pooling mechanism, where multiple Medicaid programs or insurers aggregate their eligible populations into a single negotiating unit. The European Reference Networks for rare diseases have explored analogous population-pooling strategies for centralized procurement. In the United States, a multi-state consortium modeled on the New England States Consortium Systems or similar pharmaceutical purchasing alliances could provide the scale necessary to make orphan disease subscription negotiations viable.
Chronic Disease: Diabetes as a Test Case
Chronic disease subscription models require a fundamentally different contract structure than curative-therapy subscriptions. Diabetes management involves ongoing treatment with no defined endpoint, which means a subscription must cover an indefinite or rolling treatment horizon. A five-year insulin subscription would need to account for patient population growth as new cases are diagnosed, treatment protocol changes as new formulations or dosing regimens emerge, and formulary flexibility as biosimilar insulins enter the market.
One workable structure is a population-level subscription for a defined formulary tier, covering all branded insulin products from a specific manufacturer within a negotiated annual cap, with provision for formulary expansion or substitution as the clinical landscape changes. Eli Lilly’s insulin pricing commitments in 2023, which capped out-of-pocket costs and reduced list prices, were a commercially driven approximation of this concept, though without the formal subscription architecture that a PLA requires.
Key Takeaways: Model Generalization
The PLA model’s generalizability depends on four conditions: a definable eligible patient population within a payer’s covered lives, a treatment with meaningful clinical impact, a multi-year revenue certainty benefit that offsets the manufacturer’s per-unit price discount, and administrative infrastructure to identify patients and document appropriate use. Hepatitis C and antibiotic resistance met all four conditions. Gene therapy, orphan disease, and chronic conditions meet some conditions but require structural modifications to address population scale, payment duration, and formulary flexibility.
Regulatory Barriers and How to Clear Them
The United States regulatory environment was not designed with subscription drug pricing in mind. Two specific statutory provisions create significant friction for domestic PLA implementations.
The Medicaid Drug Rebate Program and Best Price
The Medicaid Drug Rebate Program (MDRP) requires manufacturers to pay rebates to state Medicaid programs tied to the drug’s best price across all commercial customers. The best price calculation includes rebates and discounts given to any commercial purchaser, which means a deeply discounted subscription fee could trigger a best price reset that increases the manufacturer’s MDRP liability across all Medicaid transactions. This creates a strong financial disincentive for manufacturers to offer subscription pricing below their current Medicaid net price.
Louisiana and Washington both required special regulatory accommodation from the Centers for Medicare and Medicaid Services to implement their subscription programs without triggering best price implications. CMS granted these accommodations through the state plan amendment process, but the accommodations were state-specific and not transferable. A statutory or regulatory fix that explicitly carves out PLA subscription fees from best price calculations would remove this barrier for all subsequent domestic implementations.
CMS issued guidance in 2020 that created some regulatory space for value-based arrangements, but the guidance stopped short of a comprehensive best price exclusion for subscription contracts. Subsequent administrations have not moved the policy further. The absence of a clear regulatory pathway remains the single largest domestic implementation barrier for the model.
Closed Formulary Requirements and Medicaid Law
Most PLA implementations require the payer to designate the contracted product as the preferred treatment for all indicated patients, effectively creating a closed formulary for that drug class. Medicaid law generally prohibits closed formularies, which creates tension between the model’s operational requirements and federal Medicaid statute. States have navigated this through Section 1115 waiver applications, which allow CMS to approve Medicaid program modifications that do not strictly comply with standard federal requirements if they advance the program’s objectives. The waiver process is workable but time-consuming, often taking twelve to eighteen months from application to approval.
A legislative fix through a Medicaid waiver simplification provision, or a statutory amendment creating a defined subscription contracting pathway, would accelerate domestic adoption. As of March 2026, no such provision has cleared Congress, and the policy environment has not generated the bipartisan alignment that would be necessary to move it.
Procurement Law Constraints
State government procurement rules present additional barriers. Many states require competitive bidding for contracts above specified dollar thresholds, which is compatible with the Louisiana model’s design but introduces procedural timelines that slow implementation. Procurement rules in some states also require annual contract renewal rather than multi-year commitment, which conflicts with the five-year term structure that makes PLA contracts financially attractive to manufacturers.
State-level legislative amendments to pharmaceutical procurement rules, modeled on the exemptions that some states have created for value-based pharmaceutical agreements, are the most practical near-term fix. Several states are examining this approach in their 2025-2026 legislative sessions.
Key Takeaways: Regulatory Environment
The MDRP best price calculation is the primary federal regulatory barrier to U.S. PLA expansion. Removing this barrier requires either a statutory fix or durable CMS regulatory guidance. State procurement law constraints are real but addressable through state-level legislative action. Teams designing PLA programs should budget twelve to twenty-four months for regulatory clearance in the domestic context, compared to six to twelve months in markets with centralized national health systems.
Risk Allocation and the Volume Uncertainty Problem
Every PLA distributes financial risk between a payer and a manufacturer differently than traditional reimbursement. Understanding how that risk distributes is essential for both sides of the negotiation.
Volume Undershoot Risk
If actual patient treatment volume falls significantly below the projections used to set the subscription fee, the payer effectively overpays on a per-treatment basis relative to what it would have paid under volume-based pricing. This undershoot risk materializes when patient identification and care navigation infrastructure is inadequate, when clinician uptake of the contracted product is lower than projected, or when the eligible patient population was overestimated at the time of contract negotiation.
Louisiana’s initial treatment targets were aggressive given the state’s existing infrastructure. Building the care navigation programs, provider education initiatives, and patient identification mechanisms necessary to reach 10,000 patients within two years required investment that the subscription contract itself did not fund. Teams designing PLA programs should build patient identification and care navigation costs into the program budget as a separate line item, not assume that the subscription contract will generate its own patient throughput.
Volume Overshoot Risk
Manufacturers bear volume overshoot risk. If the eligible patient population grows faster than projected during the subscription term, or if a broader indication expands the treated population beyond the contracted scope, the manufacturer may treat substantially more patients than the subscription fee was priced to cover. This is a favorable outcome from a public health standpoint but a revenue risk from a manufacturer’s standpoint.
Contract language addressing population definition, indication scope, and volume adjustment mechanisms is essential to managing overshoot risk. Some contracts include utilization bands with step-up payment provisions that trigger additional fees if treatment volume exceeds defined thresholds. These provisions reduce manufacturer risk while preserving the core subscription architecture.
Information Asymmetry
The most structurally important risk in PLA negotiations is information asymmetry. Manufacturers have significantly more precise data on the drug’s treatment cost, production economics, and clinical uptake patterns than payers do. Payers often have better epidemiological data on local disease prevalence than manufacturers do. Each party has an incentive to negotiate based on their superior information while concealing it from the counterparty.
Addressing information asymmetry requires that payers invest in epidemiological modeling before entering negotiations, and that manufacturers disclose utilization projections used to derive their subscription fee proposals. Third-party validation of prevalence and cost-avoidance assumptions by neutral actuarial or health economics consultants can reduce information asymmetry enough to generate negotiated fees that both parties regard as fair.
Key Takeaways: Risk Management
PLA risk management is not primarily about contract language. It is about information quality. Payers that enter negotiations with robust disease prevalence data, realistic care navigation capacity assessments, and independent cost-avoidance calculations are positioned to negotiate fee levels that reflect realistic treatment scenarios. Manufacturers with transparent utilization projections and production cost data demonstrate good faith in ways that improve the probability of contract renewal.
Predictive Analytics as a Pricing Infrastructure
The quality of PLA negotiations and contract terms depends directly on the quality of the data underlying the pricing models. Predictive analytics has moved from a competitive advantage to an operational requirement for both sides of subscription contract negotiations.
Prevalence Modeling and Patient Identification
Accurate disease prevalence data at the payer-population level is the first analytical input to any PLA negotiation. Most state Medicaid programs have claims data that reveals diagnosed cases but systematically undercounts undiagnosed prevalence. For hepatitis C, which is asymptomatic in most patients until advanced liver disease develops, the gap between diagnosed and total infected individuals can be substantial. Louisiana’s estimates of its Medicaid HCV population were based on a combination of claims data, population surveys, and epidemiological modeling.
Predictive models using lab result patterns, demographic data, and risk factor prevalence can identify likely undiagnosed populations more accurately than claims-based counts alone. For payers, more accurate prevalence estimates reduce the risk of overpaying at subscription fee levels designed for a smaller population than actually exists. For manufacturers, they reduce the risk of underpricing for a population larger than the payer’s stated enrollment.
Cost-Avoidance Quantification
The valuation basis for PLA subscription fees is the cost avoided by treating the eligible population at scale rather than under volume-restricted rationing. Quantifying that cost avoidance requires modeling the downstream healthcare costs of untreated disease, which in hepatitis C means modeling cirrhosis rates, hepatocellular carcinoma incidence, liver transplant rates, and associated hospitalization and management costs across the projected untreated population.
IQVIA, Milliman, and similar health economics consultancies have developed proprietary models for cost-avoidance quantification in hepatitis C, and are building equivalent frameworks for other therapeutic areas where PLA contracts are under active consideration. Teams negotiating PLA contracts should use these models to establish a cost-avoidance floor below which the subscription fee has no rational basis, and a cost-avoidance ceiling above which the payer is paying more than the treatment delivers in avoided costs.
Real-Time Contract Monitoring
Once a PLA contract is in place, real-time analytics systems can track utilization against projection, identify underprescription patterns that suggest care navigation failures, and flag patient segments where treatment rates lag the program’s targets. This monitoring function is essential for program management but also for contract renegotiation. At the end of a five-year subscription term, both parties will renegotiate based on actual performance data. The party with superior analytical insight into the contract’s outcomes will have the stronger negotiating position.
Investment Strategy: What Portfolio Managers Should Track
For institutional investors and pharma portfolio managers evaluating companies with existing or potential PLA exposure, several specific metrics and structural factors affect asset valuation and revenue modeling.
PLA Revenue as a Distinct Revenue Segment
PLA-contracted revenue has a different risk profile than commercial-channel revenue. It has lower volume sensitivity (it does not respond to competitor market share gains during the contract term), lower price erosion risk from generic entry (a contract with a specific product is not automatically renegotiated when generics enter), and higher policy risk (state budget cycles, legislative changes, and Medicaid policy shifts can affect renewal probability). Modeling PLA revenue as a separate segment with distinct discount rates and risk adjustments produces more accurate valuations than folding it into the standard pharmaceutical revenue model.
Authorized Generic Strategy as a PLA Enabler
Companies that have established authorized generic subsidiaries, as Gilead did with Asegua, have a structural advantage in competing for public-payer subscription contracts. The authorized generic channel allows a branded manufacturer to offer meaningfully lower per-treatment economics in the subscription bid without setting a reference price that affects the branded product’s commercial or international pricing. Portfolio managers evaluating companies with branded drugs approaching patent expiry should assess whether the company has the authorized generic infrastructure to participate in PLA contracts as a distinct competitive capability.
IP Duration and Subscription Contract Timing
PLA contracts are most attractive to manufacturers when their patent estate has enough remaining exclusivity to recover the discounted per-treatment subscription economics. A manufacturer with eight to ten years of patent life remaining on a key asset has a larger window to generate PLA revenue before generic competition erodes the market. A manufacturer with two to three years of remaining exclusivity has less incentive to offer the discounts that make PLA contracts work for payers.
Analysts tracking PLA expansion should map patent expiry calendars for therapeutic areas under active PLA consideration, including rare neurological diseases, specialty infectious diseases, and select oncology indications, against the policy timelines for domestic and international health systems evaluating subscription models.
Renewal Probability and Programmatic Durability
The value of a five-year PLA contract depends not just on the contracted revenue but on the probability of renewal at contract expiry. Disease elimination programs with explicit statutory mandates (as Washington state’s 2030 HCV elimination goal implies) have higher renewal probability than contracts implemented purely as budget management tools. Programs that generate measurable public health improvement during the contract term are politically easier to renew than programs whose impact is primarily financial. Analysts should weight renewal probability higher for therapeutic areas with measurable epidemiological targets than for areas where the value case is primarily actuarial.
Global Replication: Australia, Sweden, and What Comes Next
Australia was the first country to implement a drug subscription model at national scale, negotiating an unlimited supply contract for hepatitis C direct-acting antivirals in 2015 as part of its commitment to eliminating HCV as a public health threat. The Australian model, administered through the Pharmaceutical Benefits Scheme, provided universal access to HCV treatment at no cost to patients. Treatment rates increased sharply in the years following implementation. Australia’s experience provided the earliest evidence that subscription models could achieve population-level disease impact rather than marginal access improvements.
Sweden’s Medical Products Agency and the Dental and Pharmaceutical Benefits Agency (TLV) have conducted formal assessments of subscription payment models for both antibiotics and rare disease treatments, drawing on the NHS antimicrobial subscription as a primary reference. TLV’s health economic framework is well-suited to cost-avoidance based subscription valuation, and Sweden’s population health registry infrastructure provides high-quality prevalence and outcome data for subscription fee negotiation.
Germany’s statutory health insurance system, organized through competing Gesetzliche Krankenversicherung funds, faces structural barriers to subscription contracting because no single national payer can commit on behalf of the full insured population. However, the Federal Joint Committee (Gemeinsamer Bundesausschuss, or G-BA) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have authority to negotiate national drug agreements that function analogously to subscription contracts for specific indications. German health economists have examined whether this authority could support PLA-style arrangements for antibiotics and gene therapies.
France’s Autorisation d’Accès Précoce (early access authorization) system has incorporated subscription-like elements for certain gene therapies and high-cost rare disease treatments, structuring payment as multi-year annuities with outcome-based adjustment provisions. While France does not use the PLA terminology, the functional architecture is closely aligned.
Key Takeaways: Global Replication
The countries best positioned to implement PLA-style subscription contracts at scale share three characteristics: a centralized or effectively centralized payer with authority to commit multi-year budgets, robust population health data infrastructure to support prevalence and cost-avoidance modeling, and a policy environment that has acknowledged the limitations of volume-based drug pricing. Australia, the UK, and Sweden meet all three criteria. Germany and France meet two of three, with Germany’s fragmented payer structure being the primary barrier and France’s early access framework providing a partial workaround.
Master Key Takeaways
On the model’s fundamentals: The Payer License Agreement is not a rebate, a discount arrangement, or a value-based payment scheme. It is a structural redesign of the pharmaceutical pricing basis. The shift from per-patient to per-population pricing changes every downstream incentive in the system: payer incentives from restriction to access, manufacturer incentives from volume defense to utilization support, and clinician incentives from prior authorization navigation to straightforward prescribing.
On IP strategy: Manufacturers whose patent estates are in the mid-to-late exclusivity window have the strongest incentive to enter PLA contracts. The authorized generic channel provides a mechanism for branded manufacturers to participate in public-payer subscription markets without triggering best price complications. Companies without authorized generic infrastructure should assess whether that gap limits their competitiveness in future subscription procurement processes.
On competitive dynamics: Subscription contracts are won through competitive bidding. The Louisiana experience established that three-bidder fields generate meaningfully better outcomes for payers than sole-source negotiations. Both payers designing PLA programs and manufacturers evaluating bid decisions should assume that effective competition will set the subscription fee at or near cost-avoidance value rather than branded list price.
On regulatory sequencing: In the United States, MDRP best price policy is the primary constraint on domestic PLA expansion. Teams should prioritize engaging CMS on the regulatory pathway before finalizing contract architecture, not after. The Section 1115 waiver process is workable but adds twelve to eighteen months to implementation timelines.
On risk: Volume undershoot is primarily a payer risk, driven by inadequate care navigation infrastructure. Volume overshoot is primarily a manufacturer risk, manageable through utilization band provisions in the contract. Information asymmetry is a bilateral risk that damages both parties and should be mitigated through third-party analytical validation before negotiations begin.
On generalization: The model works cleanly for curative or high-impact finite-course therapies in defined populations. It requires structural modification for chronic disease and gene therapy applications. The modification required for orphan disease is primarily a scale issue: cross-payer population pooling solves the problem if the political and administrative barriers to pooled procurement can be resolved.
On investment implications: PLA revenue should be modeled as a separate segment from commercial-channel revenue, with lower sensitivity to volume and competitive dynamics but higher exposure to policy risk. Renewal probability correlates with measurable public health impact, so therapeutic areas with quantifiable epidemiological targets (infection elimination, resistance reduction) carry higher renewal probability than areas where value is primarily financial.
Frequently Asked Questions
What is the difference between a PLA and a traditional rebate agreement?
A traditional pharmaceutical rebate reduces the effective net price per unit dispensed after the fact, usually calculated as a percentage of Medicaid Average Manufacturer Price. The manufacturer still receives payment for every prescription filled, and the payer’s total cost scales linearly with volume. A PLA pays a fixed annual fee for unlimited access to a drug for a defined population, making the marginal cost of each additional patient treatment zero within the contracted population. The two mechanisms produce superficially similar net price effects but entirely different utilization incentives.
How does Australia’s national HCV subscription compare with U.S. state-level implementations?
Australia negotiated its subscription model through the Pharmaceutical Benefits Scheme, a federal program covering the entire Australian population. The national scope gave the PBS substantially greater negotiating leverage than any individual U.S. state can achieve. Louisiana’s Medicaid population and Washington’s state health program each cover a fraction of the population that the PBS represents. U.S. state-level implementations have demonstrated the model’s feasibility in a fragmented payer environment but achieve less favorable terms than a national program would generate.
What happens at contract expiry under a PLA?
At the end of the subscription term, both parties renegotiate. The manufacturer has current-period revenue certainty, knowledge of actual utilization patterns, and updated clinical data for the drug’s performance in the treated population. The payer has actual cost-avoidance data, utilization history, and (in competitive markets) the ability to re-solicit bids from other manufacturers. The renegotiation dynamics favor the payer in markets with multiple competing treatment options and favor the manufacturer where the contracted drug has no close therapeutic substitute.
Can a PLA work for a drug with multiple approved indications?
A single-indication PLA is structurally simpler because the eligible patient population and the clinical benefit calculation are both well-defined. Multi-indication PLAs are theoretically possible but require population definitions that clearly separate indication groups, since the cost-avoidance valuation and the appropriate subscription fee may differ significantly across indications. Some contracts address this through separate subscription fee schedules for each indication, effectively bundling multiple single-indication PLAs into one contract.
How should manufacturers account for PLA revenue in financial reporting?
PLA revenue recognition under ASC 606 (U.S. GAAP) requires identifying the performance obligation (providing unlimited access to the drug for the contracted population over the subscription term), the transaction price (the annual subscription fee), and the period over which revenue is recognized (ratable over the contract term). Because PLAs involve ongoing performance obligations rather than point-in-time product delivery, revenue is generally recognized ratably across the subscription period rather than upon product shipment. Analysts reviewing financial statements should confirm that companies with PLA contracts are applying ratable recognition and should adjust comparisons with volume-based competitors accordingly.
Data references in this analysis draw on published research from RAND Corporation, PMC-indexed peer-reviewed literature, American Hospital Association reporting, and publicly disclosed contract terms from state Medicaid agencies. Market data and patent expiry analysis should be validated against current Orange Book filings and SEC disclosures before use in investment decisions.
